MyHealthChecked plc (AIM: MHC), the consumer home-testing healthcare company, announces that Peter Dines, Non-executive Director, has today stepped down from the Board. Peter is Chief Operating Officer at Mercia Asset Management PLC1 (“Mercia”) and is standing down to focus on other portfolio companies.
The Directorate change follows on from the successful roll-out of a new corporate strategy for growth in 2021 and beyond, which has seen MyHealthChecked focus on bringing further simple, reliable, affordable health tests to market.
Peter Dines commented: “Having been associated with the Company prior to the public listing and living through the evolution of the senior management team in recent years, I am delighted that under Penny’s leadership the company is now well placed to execute its new strategy and deliver further growth. The news today announcing the agreement with Boots is a natural time to step down in order to focus on other portfolio activities and I wish the company continued success for the future.”
Adam Reynolds, Non-executive Chairman of MyHealthChecked, said: “We are incredibly grateful for the support provided by Peter and we have benefitted enormously from his experience of commercialising and scaling exciting medtech companies. We continue to benefit from the support of Mercia, as our largest shareholder, including their participation in our most recent fundraising which will fuel the next exciting stage of our growth and evolution as we seek to become the UK’s leading business-to-consumer testing business.”
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The Directors of the Company take responsibility for this announcement.
About MyHealthChecked PLC ( www.myhealthcheckedplc.com )
MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK healthcare company with two diverse, customer-facing at-home testing brands in its portfolio:
MyHealthChecked is the umbrella brand of a range of at-home DNA and RNA tests, now in development following the recent acquisition of The Genome Store. The tests will be made available online, and would be viable for over the counter purchase.
The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market with a focus on accessibility at the right price, led by UK-based experts.
Mylo targets the personalized mobile health market, with a primary focus on hormone testing and increasing a woman’s chances of naturally getting pregnant, by enabling her to quantitively track her levels of luteinizing hormone (LH) prior to ovulation.
If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.
Terms of Website Use
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned